Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study

INTRODUCTION: Psoriasis, an incurable chronic inflammatory disease, affects over 6 million people in China. Ixekizumab, a monoclonal antibody against interleukin-17A, has demonstrated efficacy and safety for the treatment of moderate-to-severe plaque psoriasis, although limited data are available re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Li, Suyun, Ji, Yanhua, Liang, Yunsheng, Liang, Li, Deng, Lin, Dang, Chengzhi, Lv, Bingjiang, Lin, Furen, Zhang, Wendi, Shi, Jinnan, Li, Yu, Dong, Guanshen, Dou, Shi, Yuling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611864/
https://www.ncbi.nlm.nih.gov/pubmed/37824031
http://dx.doi.org/10.1007/s12325-023-02672-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611864/
https://www.ncbi.nlm.nih.gov/pubmed/37824031
http://dx.doi.org/10.1007/s12325-023-02672-1

Ejemplares similares